Abstract:OBJECTIVE:To observe the clinical efficacy of ursodeoxycholic acid (UDCA) and Fuzheng Huayu Capsule (FHC) in the treatment of primary biliary cirrhosis (PBC).METHODS:Eighty PBC patients were randomly assigned to two groups, the treatment group and the control group, 40 in each group. Patients in the treatment group took UDCA and FHC, while those in the control group were treated with UDCA alone. The treatment course was 48 weeks for both groups. The clinical symptoms and signs, liver function indices (ALT, AST, ALP, GGT, ALB, TBIL, and TBA), hepatic fibrosis indices (HA, LN, IV-CL, and PIIIP), immunologic indices (IgG, IgM, and autoimmune antibodies), changes of portal hemodynamics, and adverse reactions were observed before treatment, as well as at week 4, 12, 24, and 48 after treatment.RESULTS:After treatment the skin itching and fatigue were significantly improved in the treatment group, showing statistical difference when compared with the control group (P < 0.05, P < 0.01). After treatment the levels of ALT, AST, ALP, GGT, TBIL, and TBA obviously decreased in the two groups. They were lower in the treatment group than in the control group at the same time point (P < 0.05). The decrement was the largest at week 4. Besides, at week 48 after treatment the ALB level was improved in the treatment group (P < 0.05). The levels of HA and PIIIP obviously decreased at week 4, 12, and 24, the levels of LN and IV-C obviously decreased at week 4 and 12, the decrement of the hepatic fibrosis indices at week 4 were more obvious in the treatment group. But the levels of HA and PIIIP were lower than the pre-treatment levels at week 12 in the control group. The immunologic indices such as IgM and IgG were improved in the two groups, with better results obtained in the treatment group (P < 0.05, P < 0.01). In the treatment group ANA turned negative in 1 patient and AMA turned negative in 2 patients. After 48 weeks of treatment, the spleen was retracted, the inner diameters of the portal vein (PV) and the splenic vein (SV) were significantly reduced, and the blood flow velocity in the PV and SV increased in the treatment group (P < 0.01). At week 24 and 48, 33 patients (82.5%) and 26 patients (90.0%) in the treatment group had complete relief, better than those of the control group [22 cases (55.0%) and 28 cases (70.0%)]. No obvious adverse reaction was found in the two groups during the treatment course.CONCLUSIONS:The combination therapy of UDCA and FHC was effective and safe in anti fibrosis and improving the liver functions of PBC patients. It was safe and better than the application of UDCA alone. It was advocated to be combined use for a long term. It might improve the long-term efficacy.

Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis

Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study

Therapeutic Role of Bile Acids and Nuclear Receptor Agonists in Fibrosing Cholangiopathies

Obeticholic acid for the treatment of primary biliary cirrhosis

Letter: Bisphosphonate effectiveness in patients with cirrhosis—An emulated clinical trial

New Therapies for Primary Biliary Cirrhosis

Systematic Review and Meta-Analysis: Bezafibrate in Patients with Primary Biliary Cirrhosis.

Advances in the Treatment of Primary Biliary Cholangitis

Fibrates for the treatment of pruritus in primary biliary cholangitis: a systematic review and meta-analysis

Fibrates in the management of atherogenic dyslipidemia

[Clinical Observation on the Safety and Efficacy of Ursodeoxycholic Acid and Fuzheng Huayu Capsule in the Treatment of Primary Biliary Cirrhosis].

A randomized, controlled trial on fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid

Efficacy of adjuvant therapy with fenofibrate for primary biliary cirrhosis: a Meta-analysis

Efficacy of Fenofibrate in Chinese Patients with Primary Biliary Cirrhosis Partially Responding to Ursodeoxycholic Acid Therapy

Revisiting PPAR agonists: novel perspectives in the treatment of primary biliary cholangitis

Letter: is body-mass index really associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B?

Fenofibrate Downregulates NF-κB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary Cholangitis

Immunosuppression induces regression of fibrosis in primary biliary cholangitis with moderate-to-severe interface hepatitis

Bile acids: emerging role in management of liver diseases

Use of Fibroscan for Evaluating Efficacy of Combined Therapy with FuFang BieJia RuanGan Tablet and Antiviral Drugs in Patients with Chronic Hepatitis B Virus-related Cirrhosis

Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression